Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|JAK1 S646P||Advanced Solid Tumor||sensitive||JAK1 Inhibitor - ATP competitive||Ruxolitinib||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with Jakafi (ruxolitinib) resulted in inhibition of both Jak1 autophosphorylation and Stat3 and Erk activity, and inhibition of cell proliferation in culture in transformed cells expressing JAK1 S646P (PMID: 28410228).||28410228|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|